Corvus Pharmaceuticals Inc. (CRVS)
$12.56
$0.37
(3.04%)
As on 21-May-2026 11:36EDT
Market cap
$967 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
84,090,424
10 Years Aggregate
CFO
$-286.26 Mln
EBITDA
$-344.37 Mln
Net Profit
$-334.34 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
| 63.1 | -19.2 | -24.2 | 241.3 | 57.9 | 37.0 | -1.1 |
|
BSE Sensex
| -11.2 | -4.2 | -9.2 | -7.4 | 6.8 | 8.7 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
| 43.9 | 201.2 | 107.1 | -64.7 | -32.3 | -34.6 | 48.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
12.6 | 967.0 | 0.0 | -44.2 | -- | -28.3 | -- | 4.0 |
| 74.8 | 10,307.9 | 622.0 | -300.9 | -30.1 | -62 | -- | 17.6 | |
| 242.4 | 14,777.7 | 867.5 | 506.6 | -2.8 | -- | 27.2 | 25.9 | |
| 78.2 | 10,379.7 | 105.8 | -829.6 | -715.0 | -- | -- | 60.5 | |
| 49.4 | 12,233.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.1 | 6.5 | |
| 119.4 | 13,020.0 | 1,080.2 | -433.2 | -39.8 | -- | -- | 60.9 | |
| 300.0 | 8,785.0 | 417.3 | 225.0 | 42.8 | 18.6 | 39.9 | 6.8 | |
| 507.6 | 11,800.4 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.7 | |
| 422.3 | 11,992.5 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.4 | 20.0 | |
| 342.0 | 8,938.2 | 0.0 | -326.5 | -- | -37.2 | -- | 6.3 |
Shareholding Pattern
View DetailsAbout Corvus Pharmaceuticals (CRVS)
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's... lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California. Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080 Read more
-
Co-Founder, President, CEO & Chairman of the Board
Dr. Richard A. Miller M.D.
-
Co-Founder, President, CEO & Chairman of the Board
Dr. Richard A. Miller M.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Corvus Pharmaceuticals (CRVS)
What is the current share price of Corvus Pharmaceuticals Inc (CRVS) Today?
The share price of Corvus Pharmaceuticals Inc (CRVS) is $12.56 (NASDAQ) as of 21-May-2026 11:36 EDT. Corvus Pharmaceuticals Inc (CRVS) has given a return of 57.91% in the last 3 years.
What is the current PB & PE ratio of Corvus Pharmaceuticals Inc (CRVS)?
Since, TTM earnings of Corvus Pharmaceuticals Inc (CRVS) is negative, P/E ratio is not available.
The P/B ratio of Corvus Pharmaceuticals Inc (CRVS) is 4.01 times as on 20-May-2026, a 7 discount to its peers’ median range of 4.31 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-40.31
|
10.06
|
|
2024
|
-5.24
|
10.02
|
|
2023
|
-3.13
|
2.18
|
|
2022
|
-0.97
|
0.71
|
|
2021
|
-2.34
|
1.04
|
What is the 52 Week High and Low of Corvus Pharmaceuticals Inc (CRVS)?
The 52-week high and low of Corvus Pharmaceuticals Inc (CRVS) are Rs 26.95 and Rs 3.38 as of 21-May-2026.
What is the market cap of Corvus Pharmaceuticals Inc (CRVS)?
Corvus Pharmaceuticals Inc (CRVS) has a market capitalisation of $ 967 Mln as on 20-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Corvus Pharmaceuticals Inc (CRVS)?
Before investing in Corvus Pharmaceuticals Inc (CRVS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.